Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in . gov or VSports app下载. mil. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. V体育官网.

. 2021 Apr 6;143(14):1377-1390.
doi: 10.1161/CIRCULATIONAHA.120.050991. Epub 2021 Feb 8.

Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure: Results From the CABANA Trial

Douglas L Packer  1 , Jonathan P Piccini  2 , Kristi H Monahan  1 , Hussein R Al-Khalidi  2 , Adam P Silverstein  2 , Peter A Noseworthy  1 , Jeanne E Poole  3 , Tristram D Bahnson  2 , Kerry L Lee  2 , Daniel B Mark  2 ; CABANA Investigators
Affiliations

VSports最新版本 - Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure: Results From the CABANA Trial

Douglas L Packer (V体育官网入口) et al. Circulation. .

"VSports app下载" Abstract

Background: In patients with heart failure and atrial fibrillation (AF), several clinical trials have reported improved outcomes, including freedom from AF recurrence, quality of life, and survival, with catheter ablation. This article describes the treatment-related outcomes of the AF patients with heart failure enrolled in the CABANA trial (Catheter Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation). VSports手机版.

Methods: The CABANA trial randomized 2204 patients with AF who were ≥65 years old or <65 years old with ≥1 risk factor for stroke at 126 sites to ablation with pulmonary vein isolation or drug therapy including rate or rhythm control drugs. Of these, 778 (35%) had New York Heart Association class >II at baseline and form the subject of this article. The CABANA trial's primary end point was a composite of death, disabling stroke, serious bleeding, or cardiac arrest. V体育安卓版.

Results: Of the 778 patients with heart failure enrolled in CABANA, 378 were assigned to ablation and 400 to drug therapy. Ejection fraction at baseline was available for 571 patients (73. 0%), and 9. 3% of these had an ejection fraction <40%, whereas 11. 7% had ejection fractions between 40% and 50%. In the intention-to-treat analysis, the ablation arm had a 36% relative reduction in the primary composite end point (hazard ratio, 0. 64 [95% CI, 0. 41-0. 99]) and a 43% relative reduction in all-cause mortality (hazard ratio, 0. 57 [95% CI, 0. 33-0. 96]) compared with drug therapy alone over a median follow-up of 48. 5 months. AF recurrence was decreased with ablation (hazard ratio, 0. 56 [95% CI, 0. 42-0. 74]). The adjusted mean difference for the AFEQT (Atrial Fibrillation Effect on Quality of Life) summary score averaged over the entire 60-month follow-up was 5. 0 points, favoring the ablation arm (95% CI, 2. 5-7. 4 points), and the MAFSI (Mayo Atrial Fibrillation-Specific Symptom Inventory) frequency score difference was -2 V体育ios版. 0 points, favoring ablation (95% CI, -2. 9 to -1. 2). .

Conclusions: In patients with AF enrolled in the CABANA trial who had clinically diagnosed stable heart failure at trial entry, catheter ablation produced clinically important improvements in survival, freedom from AF recurrence, and quality of life relative to drug therapy. These results, obtained in a cohort most of whom had preserved left ventricular function, require independent trial verification. Registration: URL: https://www. clinicaltrials. gov/ct2/show/NCT00911508; Unique identifier: NCT0091150 VSports最新版本. .

Trial registration: ClinicalTrials. gov NCT00911508 NCT00911508 NCT00091150. V体育平台登录.

Keywords: antiarrhythmic drug; atrial fibrillation; catheter ablation; heart failure; paroxysmal atrial fibrillation; persistent atrial fibrillation; pulmonary vein VSports注册入口. .

PubMed Disclaimer

"VSports在线直播" Figures

Figure 1:
Figure 1:
Primary Composite End Point (Death, Disabling Stroke, Serious Bleeding, or Cardiac Arrest) Kaplan-Meier Curves by Intention-to-Treat Among CABANA Heart Failure Patients
Figure 2:
Figure 2:
All-Cause Mortality Kaplan-Meier Curves by Intention-to-Treat Among CABANA Heart Failure Patients
Figure 3:
Figure 3:
Forest Plot of Pre-specified Subgroup Comparisons in CABANA Heart Failure Patients
Figure 4:
Figure 4:
Cumulative Incidence Curves of First Recurrence of AF in the Post Blanking Period Among CABANA Heart Failure Patients Who Used the CABANA ECG Recording System
Figure 5:
Figure 5:
Atrial Fibrillation Burden by Time and Randomization Assignment Among CABANA Heart Failure Patients Who Used the CABANA ECG Recording System
Figure 6:
Figure 6:
Quality of Life Outcomes in CABANA Heart Failure Patients by MAFSI Scoring
Figure 6:
Figure 6:
Quality of Life Outcomes in CABANA Heart Failure Patients by MAFSI Scoring
See this image and copyright information in PMC

Comment in

References

    1. Skanes AC, Tang ASL. Atrial fibrillation and heart failure: untangling a modern Gordian Knot. Can J Cardiol. 2018;34:1437–48. doi: 10.1016/j.cjca.2018.07.483. - DOI - PubMed
    1. Nguyen BO, Rienstra M, Hobbelt AH, Tijssen JGP, Smit MD, Tieleman RG, Geelhoed B, Van Veldhuisen DJ, Crijns H, Van Gelder IC, et al. Optimal treatment of underlying conditions improves rhythm control outcome in atrial fibrillation - data from RACE 3. Am Heart J. 2020;226:235–239. doi: 10.1016/j.ahj.2019.12.005. - DOI - PubMed
    1. AlTurki A, Proietti R, Dawas A, Alturki H, Huynh T, Essebag V. Catheter ablation for atrial fibrillation in heart failure with reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2019;19:18. doi: 10.1186/s12872-019-0998-2. - DOI (VSports在线直播) - PMC - PubMed
    1. Di Biase L, Mohanty P, Mohanty S, Santangeli P, Trivedi C, Lakkireddy D, Reddy M, Jais P, Themistoclakis S, Dello Russo A, et al. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial. Circulation. 2016;133:1637–1644. doi: 10.1161/CIRCULATIONAHA.115.019406. - "VSports最新版本" DOI - PubMed
    1. Hunter RJ, Berriman TJ, Diab I, Kamdar R, Richmond L, Baker V, Goromonzi F, Sawhney V, Duncan E, Page SP, et al. A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial). Circ Arrhythm Electrophysiol. 2014;7:31–38. doi: 10.1161/CIRCEP.113.000806. - DOI - PubMed

Publication types

Associated data (VSports注册入口)